Loading clinical trials...

Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer

NCT00040638•Telik

Summary

The purpose of this study is to determine the effectiveness of TLK286 in the treatment of advanced non-small cell lung cancer.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histologic or cytologic diagnosis of non-small cell lung carcinoma
•Progressed while on or after treatment on platinum-based regimen
•Patients may not have had more than one prior cytotoxic chemotherapy regimen
•Stage IV or IIIB
•Age at least 18 years
•Adequate liver and kidney function
•Adequate bone marrow function

Exclusion Criteria

•Pregnancy or lactation
•Unstable medical conditions
•Chemotherapy, hormonal therapy, radiotherapy, radiopharmaceuticals or immunotherapy within 3 weeks of TLK286
•CNS metastasis unless controlled by treatment

Locations (3)

Arizona Cancer Center

Tucson, Arizona, United States

UCLA Medical Center

Los Angeles, California, United States

M.D. Anderson Cancer Center

Houston, Texas, United States

Key Dates

Start Date

July 1, 2002

Primary Completion Date

August 1, 2003

Completion Date

August 1, 2003

Last Updated

July 25, 2011

Enrollment

Estimated participants

Conditions

Carcinoma, Non-small-cell Lung

Interventions

TLK286

DRUG

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

NCT04165798

Carcinoma, Non-Small-Cell Lung

View study

RECRUITINGPHASE2

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

NCT06667908

Carcinoma, Non-Small-Cell Lung

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 25, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer

Inclusion Criteria

Exclusion Criteria

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

A Study of LY4175408 in Participants With Advanced Cancer

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)